There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evolent Health (EVH – Research Report), Vertex Pharmaceuticals (VRTX – Research Report) and Resmed (RMD – Research Report) with bullish sentiments.
Evolent Health (EVH)
RBC Capital analyst Sean Dodge maintained a Buy rating on Evolent Health on January 5 and set a price target of $42.00. The company’s shares closed last Tuesday at $32.85.
According to TipRanks.com, Dodge is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Evolent Health is a Strong Buy with an average price target of $43.78, implying a 35.6% upside from current levels. In a report issued on January 2, Barclays also initiated coverage with a Buy rating on the stock with a $39.00 price target.
See the top stocks recommended by analysts >>
Vertex Pharmaceuticals (VRTX)
Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals yesterday and set a price target of $415.00. The company’s shares closed last Tuesday at $421.01, close to its 52-week high of $422.00.
According to TipRanks.com, Brayer is a 3-star analyst with an average return of
Currently, the analyst consensus on Vertex Pharmaceuticals is a Moderate Buy with an average price target of $395.23, which is a -5.6% downside from current levels. In a report issued on January 4, Argus Research also maintained a Buy rating on the stock with a $420.00 price target.
Resmed (RMD)
J.P. Morgan analyst David Low maintained a Buy rating on Resmed yesterday and set a price target of $195.00. The company’s shares closed last Tuesday at $177.83.
According to TipRanks.com, Low is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Resmed with a $162.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EVH:
- Barclays starts healthcare technology, distribution with Neutral view
- Evolent Health initiated with an Overweight at Barclays
- 5 Top Healthcare Stocks to Buy Now, According to Analysts – December 2023
- Evolent Health management to meet with Piper Sandler
- Evolent Health initiated with bullish view at JMP Securities, here’s why
